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    Diabetes has been a major medical and health problem worldwide. Adequate glycemic control has shown a 
clinically beneficial effect for long-term prognosis, with recent anti-diabetic agents. There are some mega studies 
concerning Sodium-glucose cotransporter 2 (SGLT2) inhibitors. They are i) Canagliflozin cardioVascular 
Assessment Study (CANVAS), ii) Canagliflozin and Renal Events in Diabetes with Established Nephropathy 
Clinical Evaluation (CREDENCE), iii) Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58, iv) 
Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose 
(EMPA-REG OUTCOME) study. Current topics of SGLT2 inhibitors for cardiovascular and renal points of view 
were described. 
 
   Diabetes has been a major medical and health 
problem worldwide. The usefulness of strict glycemic 
control in early-stage after the onset of diabetes has 
been reported in UKPDS33, UKPDS34 and UKPDS80 
[1-3]. Adequate glycemic control has shown a 
beneficial effect on long-term prognosis 10-20 years 
later. On the other hand, strict glycemic control is said 
to have little benefit for patients with type 2 diabetes, 
who has diabetes for more than 10 years. These data 
can be found in three large clinical trials which are 
ACCORD, ADVANCE, and VADT [4-6]. The similar 
results have been observed in rather recent reports 
which are long-term follow-up studies [7-9]. 
Furthermore, there was a J-DOIT3 study, in which 
strict control of blood pressure, lipids and glucose 
have been continued and compared with conventional 
therapy. In this RCT study, significant improvement of 
cardiovascular prognosis was not found [10].  
 
    Regarding the target of glycemic control, the 
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American College of Physicians (ACP) has published a 
statement, in which the target HbA1c would be at 7-
8% in almost the diabetic patients [11]. The reason for 
the comment would be from a higher risk of 
hypoglycemia in previous oral medicine and the 
reduced risk of hypoglycemia in currently indicated 
anti-diabetic agents. Recently, highly safer oral 
medications have become widespread, including 
Dipeptidyl peptidase‐4 (DPP‐4) inhibitors and 
Sodium-glucose cotransporter 2 (SGLT2) inhibitors. 
Authors and colleagues have reported the clinical 
efficacy of SGLT2 inhibitor for glucose variability in 
rather a short period [12]. Current topics on these 
drugs are described in this article.  
 
    There are some mega studies concerning SGLT2 
inhibitors. They are i) Canagliflozin cardioVascular 
Assessment Study (CANVAS), ii) Canagliflozin and 
Renal Events in Diabetes with Established 
Nephropathy Clinical Evaluation (CREDENCE), iii) 
Dapagliflozin Effect on CardiovascuLAR Events 
(DECLARE) -TIMI 58, iv) Empagliflozin 
Cardiovascular Outcome Event Trial in Type 2 
Diabetes Mellitus Patients-Removing Excess Glucose 
(EMPA-REG OUTCOME) study. 
 
    Concerning the SGLT2 inhibitor, this was known as 
CREDENCE Clinical Trials [13]. Patients with T2DM 
and albuminuric CKD were assigned to receive 
canagliflozin. They included 4401 subjects with 63 
years old on average. Subjects were divided randomly 
into two groups, which were the canagliflozin group 
and the placebo group. The relative risk of primary 
outcome was 30% lower in the former group (Hazard 
ratio (HR) 0.70 [95% CI: 0.59 to 0.82]). A doubling of 
creatinine level or death from renal causes was lower 
by 34% (HR 0.66 [95% CI 0.53 to 0.81]), and the 
relative risk of end-stage kidney disease was lower by 
32% (HR 0.68 [95% Cl 0.54 to 0.86]). The former 
group showed a lower risk of cardiovascular death, 
myocardial infarct, and stroke (HR 0.80), 
hospitalization from heart failure (HR 0.61). In 
contrast, no significant differences were found in rates 
of amputation (HR 1.11) or fracture (HR 0.98).  
 
    As to the effects of SGLT2 inhibitors in renal 
failure, there was a systematic review and meta-
analysis of randomized, controlled, cardiovascular or 
kidney outcome trials [14]. From data of 2085 
records, four studies had met the inclusion criteria. 
They included three SGLT2 inhibitors, which were 
empagliflozin (EMPA-REG OUTCOME) [15,16], 
canagliflozin (CANVAS Program and CREDENCE) 
[17], and dapagliflozin (DECLARE-TIMI 58) [18,19]. 
Among them, there included 38,723 subjects, 335 end-
stage kidney disease, and 252 dialysis or 
transplantation or died of kidney disease. By the 
administration of SGLT2 inhibitors, the risk of 
required dialysis was reduced by 33% (HR 0.67). 
Further, the risk of end-stage kidney disease and acute 
kidney injury was reduced (HR 0.65, and 0.75, 
respectively). Consequently, SGLT2 inhibitors 
decreased the risk of dialysis, transplantation, or 
death due to kidney disease. These results suggest the 
substantive evidence of SGLT2 inhibitors for 
preventing major kidney outcomes in T2DM. 
 
    Furthermore, a systematic review and meta-
analysis was reported to assess the efficacy and safety 
of SGLT2 inhibitors for T2DM and CKD [20]. Patients 
were selected as estimated glomerular filtration rate 
(eGFR) <60 mL/min/1.73 m2. As a result, data was 
collected from 7363 participants in 27 studies. SGLT2 
inhibitors decreased HbA1c by 0.29% with body 
weight, blood pressure, and albuminuria. SGLT 
inhibitors reduced the risk of cardiovascular death, 
nonfatal myocardial infarction or nonfatal stroke (RR, 
0.81) and heart failure (RR, 0.61). Moreover, SGLT 
inhibitors reduced the declined slope of eGFR a year 
and decreased the risk of the composite renal outcome 
(HR 0.71) [20]. Consequently, SGLT2 inhibitors can 
reduce the risk of cardiovascular and renal 
exacerbation in T2DM and CKD, without evidence of 
additional safety concerns. 
 
    According to the primary analysis of the CANVAS, 
canagliflozin showed a beneficial effect on 
cardiovascular and renal outcomes in T2DM [17,13]. 
However, it showed an increased risk of lower 
extremity amputation. Consequently, the secondary 
analyses were conducted [21]. There were 187 (1.8%) 
participants with atraumatic lower extremity 
amputations (minor 71%, major 29%), and the rates 
were 6.30 vs 3.37 / 1000 participant-years with two 
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groups of canagliflozin vs placebo (HR 1.97 [95% CI 
1.41 to 2.75]). The risk was similar to those of 
ischemic and infective etiologies and to 100 mg and 
300 mg doses. Anticipated risk factors for amputation 
were identified, including a prior history of 
amputation (HR 21.31 [95% CI 15.40 to 29.49]), 
peripheral vascular disease and neuropathy. However, 
there was no specific etiological mechanism or at-risk 
subgroup for canagliflozin. 
 
    Furthermore, the study of the risk for lower limb 
amputations with SGLT-2 inhibitors were conducted 
[22]. A total of 27 trials were collected and 
investigated. They include Canagliflozin, 
Dapagliflozin, Empagliflozin, Ertuglifozin and 
analyzed cases were 29407 cases in the SGLT2 group 
and 21556 cases in the control group. The overall 
incidence of peripheral artery disease (PAD) was 
increased with SGLT-2 inhibitors, in which the 
Mantel-Haenszel odds ratio (MH-OR) with 95% 
Confidence Interval was 1.26 (1.04, 1.52). The increase 
in risk was statistically significant only with 
canagliflozin. MH-OR for amputation in the 
cardiovascular safety trials with SGLT-2 inhibitors 
was 1.22 [0.59-2.52] (not significant). Consequently, 
there is no reason to believe that empagliflozin or 
dapagliflozin increases the risk of either PAD of lower 
limb amputations. Canagliflozin could be associated 
with a specific risk, which needs to be further 
investigated [22]. 
 
    There was a study for whether SGLT2-I are 
associated with a higher risk of lower-extremity 
amputation than DPP-4 inhibitors and sulphonylureas 
[23]. It was a retrospective cohort study, from 328,150 
applicants aged 18-64. As a result, the estimated 
hazard of lower-extremity amputation was increased 
in SGLT2 inhibitors compared to DPP-4 inhibitors 
(adjusted Hazard Ratio (aHR) 1.69, 95% CI 1.20-2.38). 
In contrast, it was a similar value (aHR 1.02) or non-
metformin, non-SGLT2 inhibitors (aHR 1.02). 
 
    In summary, recent topics for the effects of SGLT2 
inhibitors on cardiovascular and renal function were 
introduced. We hope that this description will help 
future diabetes care and research. 
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